Ranexa Approved - CV Therapeutics, Inc. - Treatment for Chronic Angina
Ranexa is a novel antianginal and anti-ischemic agent indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs.Related Articles:
FDA Approves Ranexa for First Line Anti Anginal Use - November 6, 2008
FDA Approves New Mechanism of Action Labeling for Ranexa - December 19, 2007
CV Therapeutics Launches 1000 mg Ranexa Tablet - August 14, 2007
CV Therapeutics Submits Amendment to Ranexa (ranolazine) - July 27, 2005
FDA Drug Approvals Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Aug | Oct | Dec
